

US00RE43258E

(19) **United States**  
 (12) **Reissued Patent**  
**Truncale et al.**

(10) **Patent Number:** **US RE43,258 E**  
 (45) **Date of Reissued Patent:** **\*Mar. 20, 2012**

(54) **GLUE FOR CARTILAGE REPAIR**

(75) Inventors: **Katherine G. Truncale**, Hillsborough, NJ (US); **Moon Hae Sunwoo**, Old Tappan, NJ (US); **Arthur A. Gertzman**, Flemington, NJ (US); **William W. Tomford**, Belmont, MA (US)

(73) Assignee: **Musculoskeletal Transplant Foundation**, Edison, NJ (US)

(\* ) Notice: This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/966,674**

(22) Filed: **Dec. 13, 2010**

**Related U.S. Patent Documents**

Reissue of:

(64) Patent No.: **7,067,123**  
 Issued: **Jun. 27, 2006**  
 Appl. No.: **10/424,765**  
 Filed: **Apr. 29, 2003**

U.S. Applications:

(63) Continuation of application No. 12/147,042, filed on Jun. 26, 2008, now Pat. No. Re. 42,208.

(51) **Int. Cl.**  
**A61K 35/32** (2006.01)

(52) **U.S. Cl.** ..... **424/548**; 424/93.7

(58) **Field of Classification Search** ..... None  
 See application file for complete search history.

(56) **References Cited**

## U.S. PATENT DOCUMENTS

3,400,199 A	9/1968	Balassa
3,476,855 A	11/1969	Balassa
3,478,146 A	11/1969	Balassa
3,551,560 A	12/1970	Theile
3,772,432 A	11/1973	Balassa
3,867,728 A	2/1975	Stubstad et al.
3,966,908 A	6/1976	Balassa
4,060,081 A	11/1977	Yannas et al.
4,172,128 A	10/1979	Thiele et al.
4,201,845 A	5/1980	Feder et al.
4,296,100 A	10/1981	Franco
4,378,347 A	3/1983	Franco
4,394,370 A	7/1983	Jefferies
4,400,833 A	8/1983	Kurland
4,442,655 A	4/1984	Stroetmann
4,458,678 A	7/1984	Yannas et al.
4,479,271 A	10/1984	Bolesky et al.
4,501,269 A	2/1985	Bagby
4,505,266 A	3/1985	Yannas et al.
4,600,574 A	7/1986	Lindner et al.
4,609,551 A	9/1986	Caplan et al.
4,627,853 A	12/1986	Campbell et al.

4,642,120 A	2/1987	Nevo et al.
4,656,137 A	4/1987	Balassa
4,681,763 A	7/1987	Nathanson et al.
4,683,195 A	7/1987	Mullis et al.
4,683,202 A	7/1987	Mullis
4,757,017 A	7/1988	Cheung
4,776,173 A	10/1988	Kamarei et al.
4,776,853 A	10/1988	Klement et al.
4,795,467 A	1/1989	Piez et al.
4,801,299 A	1/1989	Brendel et al.
4,837,379 A	6/1989	Weinberg
4,846,835 A	7/1989	Grande
4,880,429 A	11/1989	Stone
4,902,508 A	2/1990	Badylak et al.
4,904,259 A	2/1990	Itay
4,932,973 A	6/1990	Gendler
4,950,296 A	8/1990	McIntyre
4,950,483 A	8/1990	Ksander et al.
4,955,911 A	9/1990	Frey et al.
4,963,146 A	10/1990	Li
4,963,489 A	10/1990	Naughton et al.
4,965,188 A	10/1990	Mussis et al.
4,971,954 A	11/1990	Brodsky et al.
4,976,738 A	12/1990	Frey et al.
4,978,355 A	12/1990	Frey et al.
4,994,084 A	2/1991	Brennan
4,994,559 A	2/1991	Moscattelli et al.
5,002,071 A	3/1991	Harrell
5,002,583 A	3/1991	Pitaru et al.
5,007,934 A	4/1991	Stone

(Continued)

## FOREIGN PATENT DOCUMENTS

EP 0517030 A2 12/1992

(Continued)

## OTHER PUBLICATIONS

(No Author) "Lyophilization" TechnoBusiness-Solutions. (No publication date). Retrieved Jul. 1, 2009 from URL: <http://www.technobusiness-solutions.com/article-lyophilization1.html>> 10 pages.\*

(Continued)

*Primary Examiner* — Allison Ford(74) *Attorney, Agent, or Firm* — Greenberg Traurig LLP(57) **ABSTRACT**

The invention is directed toward a sterile cartilage defect implant material comprising milled lyophilized allograft cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers with allogenic chondrocytes or bone marrow cells in an amount exceeding the natural occurrence of same in hyaline cartilage and adding a cell growth additive.

**71 Claims, 1 Drawing Sheet**

## US RE43,258 E

Page 2

U.S. PATENT DOCUMENTS							
5,032,508	A	7/1991	Naughton et al.	5,700,774	A	12/1997	Hattersley et al.
5,041,138	A	8/1991	Vacanti et al.	5,707,962	A	1/1998	Chen et al.
5,053,049	A	10/1991	Campbell	5,713,374	A	2/1998	Pachence et al.
5,053,050	A	10/1991	Itay	5,716,413	A	2/1998	Walter et al.
5,067,963	A	11/1991	Khoury et al.	5,723,331	A	3/1998	Tube et al.
5,067,964	A	11/1991	Richmond et al.	5,728,159	A	3/1998	Stroeve et al.
5,073,373	A	12/1991	O'Leary et al.	5,733,337	A	3/1998	Carr, Jr. et al.
5,084,051	A	1/1992	Tormala et al.	5,736,132	A	4/1998	Juergensen et al.
5,092,887	A	3/1992	Gendler	5,736,372	A	4/1998	Vacanti et al.
5,118,512	A	6/1992	O'Leary et al.	5,736,396	A	4/1998	Bruder et al.
5,152,791	A	10/1992	Hakamatsuka et al.	5,749,874	A	5/1998	Schwartz
5,155,214	A	10/1992	Baird et al.	5,755,791	A	5/1998	Whitson et al.
5,191,067	A	3/1993	Lappi et al.	5,759,190	A	6/1998	Vibe-Hansen et al.
5,195,892	A	3/1993	Gershberg	5,769,899	A	6/1998	Schwartz et al.
5,206,023	A	4/1993	Hunziker	5,770,417	A	6/1998	Vacanti et al.
5,226,914	A	7/1993	Caplan et al.	5,782,835	A	7/1998	Hart et al.
5,236,456	A	8/1993	O'Leary et al.	5,782,915	A	7/1998	Stone
5,256,140	A	10/1993	Fallick	5,786,217	A	7/1998	Tube et al.
5,260,420	A	11/1993	Burnouf-Radosevich et al.	5,788,625	A	8/1998	Plouhar et al.
5,266,476	A	11/1993	Sussman et al.	5,800,537	A	9/1998	Bell
5,270,300	A	12/1993	Hunziker	5,814,084	A	9/1998	Grivas et al.
5,275,826	A	1/1994	Badylak et al.	5,842,477	A	12/1998	Naughton et al.
5,281,422	A	1/1994	Badylak et al.	5,846,931	A	12/1998	Hattersley et al.
5,284,155	A	2/1994	Treadwell et al.	5,853,746	A	12/1998	Hunziker
5,290,558	A	3/1994	O'Leary et al.	5,855,620	A	1/1999	Bishopric et al.
5,298,254	A	3/1994	Prewett et al.	5,859,208	A	1/1999	Fiddes et al.
5,302,702	A	4/1994	Seddon et al.	5,863,296	A	1/1999	Orton
5,306,304	A	4/1994	Gendler	5,863,297	A	1/1999	Walter et al.
5,306,311	A	4/1994	Stone et al.	5,866,415	A	2/1999	Villeneuve
5,310,883	A	5/1994	Seddon et al.	5,876,452	A	3/1999	Athanasidou et al.
5,314,476	A	5/1994	Prewett et al.	5,881,733	A	3/1999	Stone
5,326,357	A	7/1994	Kandel	5,888,219	A	3/1999	Bonutti
5,329,846	A	7/1994	Bonutti	5,891,558	A	4/1999	Bell et al.
5,336,616	A	8/1994	Livesey et al.	5,893,888	A	4/1999	Bell
5,338,772	A	8/1994	Bauer et al.	5,899,936	A	5/1999	Goldstein
5,352,463	A	10/1994	Badylak et al.	5,899,939	A	5/1999	Boyce et al.
5,354,557	A	10/1994	Oppermann et al.	5,904,716	A	5/1999	Gendler
5,356,629	A	10/1994	Sander et al.	5,906,827	A	5/1999	Khoury et al.
5,368,858	A	11/1994	Hunziker	5,910,315	A	6/1999	Stevenson et al.
5,372,821	A	12/1994	Badylak et al.	5,916,265	A	6/1999	Hu
5,380,328	A	1/1995	Morgan	5,922,028	A	7/1999	Plouhar et al.
5,411,885	A	5/1995	Marx	5,948,429	A	9/1999	Bell et al.
5,425,769	A	6/1995	Snyders, Jr.	5,955,438	A	9/1999	Pitaru et al.
5,439,684	A	8/1995	Prewett et al.	5,964,805	A	10/1999	Stone
5,439,818	A	8/1995	Fiddes et al.	5,968,556	A	10/1999	Atala et al.
5,443,950	A	8/1995	Naughton et al.	5,972,368	A	10/1999	McKay
5,445,833	A	8/1995	Badylak et al.	5,972,385	A	10/1999	Liu et al.
5,464,439	A	11/1995	Gendler	5,974,663	A	11/1999	Ikeda et al.
5,466,462	A	11/1995	Rosenthal et al.	5,989,269	A	11/1999	Vibe-Hansen et al.
5,491,220	A	2/1996	Seddon et al.	5,989,289	A	11/1999	Coates et al.
5,496,722	A	3/1996	Goodwin et al.	5,989,866	A	11/1999	Deisher et al.
5,507,813	A	4/1996	Dowd et al.	5,998,170	A	12/1999	Arakawa et al.
5,510,396	A	4/1996	Prewett et al.	6,001,352	A	12/1999	Boyan et al.
5,512,460	A	4/1996	Nauro et al.	6,005,161	A	12/1999	Brekke et al.
5,513,662	A	5/1996	Morse et al.	6,013,853	A	1/2000	Athanasidou et al.
5,516,532	A	5/1996	Atala et al.	6,017,348	A	1/2000	Hart et al.
5,516,533	A	5/1996	Badylak et al.	6,025,334	A	2/2000	Dupont et al.
5,545,222	A	8/1996	Bonutti	6,025,538	A	2/2000	Yaccarino, III
5,549,904	A	8/1996	Juergensen et al.	6,027,743	A	2/2000	Khoury et al.
5,554,389	A	9/1996	Badylak et al.	6,030,635	A	2/2000	Gertzman et al.
5,556,430	A	9/1996	Gendler	6,037,171	A	3/2000	Larsson
5,569,272	A	10/1996	Reed et al.	6,039,762	A	3/2000	McKay
5,571,895	A	11/1996	Kurokawa et al.	6,056,777	A	5/2000	McDowell
5,576,288	A	11/1996	Lappi et al.	6,060,640	A	5/2000	Pauley et al.
5,604,293	A	2/1997	Fiddes et al.	6,074,663	A	6/2000	Delmotte et al.
5,607,474	A	3/1997	Athanasidou et al.	6,080,194	A	6/2000	Pachence et al.
5,614,496	A	3/1997	Dunstan et al.	6,090,996	A	7/2000	Li
5,618,925	A	4/1997	Dupont et al.	6,090,998	A	7/2000	Grooms et al.
5,622,928	A	4/1997	Naruo et al.	6,096,081	A	8/2000	Grivas et al.
5,624,463	A	4/1997	Stone et al.	6,096,347	A	8/2000	Geddes et al.
5,631,011	A	5/1997	Wadstrom	6,110,209	A	8/2000	Stone
5,632,745	A	5/1997	Schwartz	6,110,482	A	8/2000	Khoury et al.
5,656,598	A	8/1997	Dunstan et al.	6,123,731	A	9/2000	Boyce et al.
5,662,710	A	9/1997	Bonutti	6,132,472	A	10/2000	Bonutti
5,679,637	A	10/1997	Lappi et al.	6,143,293	A	11/2000	Weiss et al.
5,681,353	A	10/1997	Li et al.	6,146,385	A	11/2000	Torrie et al.
5,695,998	A	12/1997	Badylak et al.	6,156,068	A	12/2000	Walter et al.
5,700,476	A	12/1997	Rosenthal et al.	6,165,486	A	12/2000	Marra et al.
				6,165,487	A	12/2000	Ashkar et al.



# US RE43,258 E

Page 4

RE39,587 E	4/2007	Gertzman et al.	2002/0082704 A1	6/2002	Cerundolo
7,201,917 B2	4/2007	Malaviya et al.	2002/0099448 A1	7/2002	Hiles et al.
7,217,294 B2	5/2007	Kusanagi et al.	2002/0106393 A1	8/2002	Bianchi et al.
7,220,558 B2	5/2007	Luyten et al.	2002/0111695 A1	8/2002	Kandel
7,226,482 B2	6/2007	Messerli et al.	2002/0120274 A1	8/2002	Overaker et al.
7,241,316 B2	7/2007	Evans et al.	2002/0138143 A1	9/2002	Grooms et al.
7,252,987 B2	8/2007	Bachalo et al.	2002/0177224 A1	11/2002	Madry et al.
7,264,634 B2	9/2007	Schmieding	2002/0192263 A1	12/2002	Merboth et al.
7,273,756 B2	9/2007	Adkisson et al.	2003/0021827 A1	1/2003	Malaviya et al.
7,288,406 B2	10/2007	Bogin et al.	2003/0023316 A1	1/2003	Brown et al.
7,291,169 B2	11/2007	Hodorek	2003/0032961 A1	2/2003	Pelo et al.
7,297,161 B2	11/2007	Fell	2003/0033021 A1	2/2003	Plouhar et al.
7,316,822 B2	1/2008	Binette et al.	2003/0033022 A1	2/2003	Plouhar et al.
7,323,011 B2	1/2008	Shepard et al.	2003/0036797 A1	2/2003	Malaviya et al.
7,323,445 B2	1/2008	Zhang et al.	2003/0036801 A1	2/2003	Schwartz et al.
7,335,508 B2	2/2008	Yayon et al.	2003/0039695 A1	2/2003	Geistlich et al.
7,338,492 B2	3/2008	Singhatat	2003/0040113 A1	2/2003	Muzuno et al.
7,338,524 B2	3/2008	Fell et al.	2003/0044444 A1	3/2003	Malaviya et al.
7,358,284 B2	4/2008	Griffey et al.	2003/0049299 A1	3/2003	Malaviya et al.
7,361,195 B2	4/2008	Schwartz et al.	2003/0050709 A1	3/2003	Noth et al.
7,365,051 B2	4/2008	Paulista et al.	2003/0055502 A1	3/2003	Lang et al.
7,371,400 B2	5/2008	Borenstein et al.	2003/0077281 A1	4/2003	Sah et al.
7,416,889 B2	8/2008	Ciombor et al.	2003/0078617 A1	4/2003	Schwartz et al.
7,468,075 B2	12/2008	Lang et al.	2003/0099620 A1	5/2003	Zaleske et al.
7,468,192 B2	12/2008	Mizuno et al.	2003/0144743 A1	7/2003	Edwards et al.
7,476,257 B2	1/2009	Sah et al.	2003/0229400 A1	12/2003	Masuda et al.
7,479,160 B2	1/2009	Branch et al.	2003/0236573 A1	12/2003	Evans et al.
7,485,310 B2	2/2009	Luyten et al.	2004/0028717 A1	2/2004	Sittinger et al.
7,488,348 B2	2/2009	Truncale et al.	2004/0033212 A1	2/2004	Thomson et al.
7,513,910 B2	4/2009	Buskirk et al.	2004/0039447 A1	2/2004	Simon et al.
7,531,000 B2	5/2009	Hodorek	2004/0044408 A1	3/2004	Hungerford et al.
7,537,617 B2	5/2009	Bindsell et al.	2004/0062753 A1	4/2004	Rezania et al.
7,537,780 B2	5/2009	Mizuno et al.	2004/0078090 A1	4/2004	Binette et al.
7,548,865 B2	6/2009	Schmieding	2004/0102850 A1	5/2004	Shepard
7,550,007 B2	6/2009	Malinin	2004/0107003 A1	6/2004	Boyer, II et al.
7,563,455 B2	7/2009	McKay	2004/0115172 A1	6/2004	Bianchi et al.
7,563,769 B2	7/2009	Bogin et al.	2004/0127987 A1	7/2004	Evans et al.
7,601,173 B2	10/2009	Messerli et al.	2004/0134502 A1	7/2004	Mizuno et al.
7,608,113 B2	10/2009	Boyer, II et al.	2004/0138748 A1	7/2004	Boyer, II et al.
7,621,963 B2	11/2009	Simon et al.	2004/0143344 A1	7/2004	Malaviya et al.
7,622,438 B1	11/2009	Lazarov et al.	2004/0151705 A1	8/2004	Mizuno et al.
7,622,562 B2	11/2009	Thorne et al.	2004/0166169 A1	8/2004	Malaviya et al.
7,628,851 B2	12/2009	Armitage et al.	2004/0170610 A1	9/2004	Slavin et al.
7,632,311 B2	12/2009	Seedhom et al.	2004/0175826 A1	9/2004	Maor
7,638,486 B2	12/2009	Lazarov et al.	2004/0192605 A1	9/2004	Zhang et al.
7,642,092 B2	1/2010	Maor	2004/0193268 A1	9/2004	Hazebrouck
7,648,700 B2	1/2010	Vignery et al.	2004/0197311 A1	10/2004	Brekke et al.
7,648,965 B2	1/2010	Vignery et al.	2004/0197373 A1	10/2004	Gertzman et al.
7,658,768 B2	2/2010	Miller et al.	2004/0219182 A1	11/2004	Gomes et al.
7,662,184 B2	2/2010	Edwards et al.	2004/0220574 A1	11/2004	Pelo et al.
7,666,230 B2	2/2010	Orban et al.	2004/0230303 A1	11/2004	Gomes et al.
RE41,286 E	4/2010	Atkinson et al.	2004/0243242 A1	12/2004	Sybert et al.
7,815,926 B2	10/2010	Syring et al.	2005/0004672 A1	1/2005	Pafford et al.
7,824,701 B2	11/2010	Binette et al.	2005/0020500 A1	1/2005	Shen et al.
7,837,740 B2	11/2010	Semler et al.	2005/0027307 A1	2/2005	Schwartz et al.
7,875,296 B2	1/2011	Binette et al.	2005/0043814 A1	2/2005	Kusanagi et al.
7,901,457 B2	3/2011	Truncale et al.	2005/0064042 A1	3/2005	Vunjak-Novakovic et al.
7,901,461 B2	3/2011	Harmon et al.	2005/0074476 A1	4/2005	Gendler et al.
2001/0005592 A1	6/2001	Bhatnagar et al.	2005/0074481 A1	4/2005	Brekke et al.
2001/0006634 A1	7/2001	Zaleske et al.	2005/0089544 A1	4/2005	Khoury et al.
2001/0010023 A1	7/2001	Schwartz et al.	2005/0101957 A1	5/2005	Buskirk et al.
2001/0011131 A1	8/2001	Luyten et al.	2005/0112761 A1	5/2005	Halvorsen et al.
2001/0016646 A1	8/2001	Rueger et al.	2005/0125077 A1	6/2005	Harmon et al.
2001/0018619 A1	8/2001	Enzerink et al.	2005/0129668 A1	6/2005	Giannetti et al.
2001/0020188 A1	9/2001	Sander	2005/0152882 A1	7/2005	Kizer et al.
2001/0021875 A1	9/2001	Enzerink et al.	2005/0159820 A1	7/2005	Yoshikawa et al.
2001/0031254 A1	10/2001	Bianchi et al.	2005/0159822 A1	7/2005	Griffey et al.
2001/0039457 A1	11/2001	Boyer, II et al.	2005/0196460 A1	9/2005	Malinin
2001/0039458 A1	11/2001	Boyer, II et al.	2005/0209705 A1	9/2005	Niederauer et al.
2001/0041941 A1	11/2001	Boyer, II et al.	2005/0222687 A1	10/2005	Vunjak-Novakovic et al.
2001/0043940 A1	11/2001	Boyce et al.	2005/0228498 A1	10/2005	Andres
2001/0051834 A1	12/2001	Frondoza et al.	2005/0240281 A1	10/2005	Slivka et al.
2002/0009805 A1	1/2002	Nevo et al.	2005/0251268 A1	11/2005	Truncale
2002/0016592 A1	2/2002	Branch et al.	2005/0260612 A1	11/2005	Padmini et al.
2002/0035401 A1	3/2002	Boyce et al.	2005/0261681 A9	11/2005	Branch et al.
2002/0042373 A1	4/2002	Carney et al.	2005/0261767 A1	11/2005	Anderson et al.
2002/0045940 A1	4/2002	Giannetti et al.	2005/0288796 A1	12/2005	Awad et al.
2002/0055783 A1	5/2002	Tallarida et al.	2006/0030948 A1	2/2006	Manrique et al.
2002/0072806 A1	6/2002	Buskirk et al.	2006/0060209 A1	3/2006	Shepard



WO	01/39788	A2	6/2001
WO	01/43667	A1	6/2001
WO	01/46416	A1	6/2001
WO	02/18546	A2	3/2002
WO	02/22779	A2	3/2002
WO	02/036732	A2	5/2002
WO	02/058484	A2	8/2002
WO	02/064180	A1	8/2002
WO	02/077199	A2	10/2002
WO	02/095019	A1	11/2002
WO	03/007805	A2	1/2003
WO	03/007873	A2	1/2003
WO	03/007879	A2	1/2003
WO	WO 03/007805	A2	1/2003
WO	WO 03/007805	A3	1/2003
WO	WO 03/007879	A2	1/2003
WO	03/012053	A2	2/2003
WO	03/007879	A3	8/2003
WO	03/079985	A2	10/2003
WO	03/087160	A1	10/2003
WO	03/094835	A2	11/2003
WO	03/007805	A3	2/2004
WO	2004/067704	A2	8/2004
WO	2004/069298	A1	8/2004
WO	2004/075940	A1	9/2004
WO	2004/096983	A2	11/2004
WO	2004/103224	A1	12/2004
WO	2005058207	A1	6/2005
WO	2005/110278	A2	11/2005
WO	2004/096983	A3	12/2005
WO	2006/036681	A2	4/2006
WO	2006/042311	A2	4/2006
WO	2006/050213	A2	5/2006
WO	2005/110278	A3	8/2006
WO	02/036732	A3	9/2006
WO	2006/113586	A2	10/2006
WO	2006/042311	A3	11/2006
WO	03/094835	A3	12/2006
WO	2007/024238	A1	3/2007
WO	2006/113586	A3	7/2007
WO	2008/013763	A2	1/2008
WO	2008/021127	A2	2/2008
WO	2008/013763	A3	4/2008
WO	2008/038287	A2	4/2008
WO	2008/081463	A2	7/2008
WO	2008/106254	A2	9/2008
WO	2008/038287	A3	4/2009
WO	2009/076164	A2	6/2009
WO	2009/111069	A1	9/2009
WO	2009/155232	A1	12/2009
WO	2010/083051	A2	7/2010

## OTHER PUBLICATIONS

Aston et al., "Repair of Articular Surfaces by Allografts of Articular and Growth-Plate Cartilage," *Journal of Bone and Joint Surgery*, Jan. 1986, vol. 68-B, No. 1; pp. 29-35.

Hoffman, "Hydrogels for Biomedical Applications," *Advanced Drug Delivery Reviews*, 2002, vol. 43, pp. 3-12.

Dahlberg et al., "Deminerlized Allogeneic Bone Matrix for Cartilage Repair", *Journal of Orthopaedic Research*, 1991, vol. 9, pp. 11-19.

Lu et al., "Minced Cartilage without Cell Culture Serves as an Effective Intraoperative Cell Source for Cartilage Repair", *Journal of Orthopaedic Research*, Jun. 2006, vol. 24, pp. 1261-1270.

Stone et al., "Articular Cartilage Paste Grafting to Full-Thickness Articular Cartilage Knee Joint Lesions: A 2- to 12-Year Follow-up", *Arthroscopy: The Journal of Arthroscopic and Related Surgery*, Mar. 2006, vol. 22, No. 3, pp. 291-299.

Newman, "Articular Cartilage Repair", *American Journal of Sports Medicine*, 1998, vol. 26, No. 2, pp. 309-324.

Brittberg et al., "Treatment of Deep Cartilage Defects in the Knee with Autologous Chondrocyte Transplantation", *New England Journal of Medicine*, Oct. 6, 1994, vol. 331, No. 14, pp. 889-895.

Nixon et al., "Enhanced Repair of Extensive Articular Defects by Insulin-like Growth Factor-I-Laden Fibrin Composites", *Journal of Orthopaedic Research*, 1999; 17:475-487.

International Cartilage Repair Society, "Cartilage Injury Evaluation Package", [www.cartilage.org](http://www.cartilage.org), 2000.

Richardson et al., "Repair of Human Articular Cartilage After Implantation of Autologous Chondrocytes", *Journal of Bone and Joint Surgery [Br]*, 1999; 81-B:1064-1068.

Brittberg et al., "Autologous Chondrocytes Used for Articular Cartilage Repair: An Update", *Clinical Orthopaedics and Related Research*, 2001; No. 391 Suppl: S337-S348.

Peterson et al., "Two- to 9-year Outcome After Autologous Chondrocyte Transplantation of the Knee", *Clinical Orthopaedics and Related Research*, 2000; No. 374: 212-234.

Peterson et al., "Autologous Chondrocyte Transplantation: Biomechanics and Long-term Durability", *American Journal of Sports Medicine*, 2002, vol. 30, No. 1, pp. 2-12.

Messner et al., "Cartilage Repair: A Critical Review", *Acta Orthopaedica Scandinavica*, 1996, vol. 67, No. 5, pp. 523-529.

Messner et al., "The Long-term Prognosis for Severe Damage to Weight-bearing Cartilage in the Knee: A 14-year Clinical and Radiographic Follow-up in 28 Young Athletes", *Acta Orthopaedica Scandinavica*, 1996, vol. 67, No. 2, pp. 165-168.

Buckwalter et al., "Articular Cartilage: Degeneration and Osteoarthritis, Repair, Regeneration, and Transplantation", *AAOS Instructional Course Lectures*, 1998; 47:487-504.

Breinan et al., "Effect of Cultured Autologous Chondrocytes on Repair of Chondral Defects in a Canine Model", *Journal of Bone and Joint Surgery [Am]*, Oct. 1997; vol. 79-A, No. 10, 1439-1451.

Breinan et al., "Autologous Chondrocyte Implantation in a Canine Model: Change in Composition of Reparative Tissue with Time", *Journal of Orthopaedic Research*, 2001; 19:482-492.

Brittberg et al., "Rabbit Articular Cartilage Defects Treated with Autologous Cultured Chondrocytes", *Clinical Orthopaedics and Related Research*, 1996; 326:270-283.

Nehrer et al., "Chondrocyte-seeded Collagen Matrices Implanted in a Chondral Defect in a Canine Model", *Biomaterials*, 1998; 19:2313-2328.

Vunjak-Novakovic et al., "Bioreactor Cultivation Conditions Modulate the Composition and Mechanical Properties of Tissue-Engineered Cartilage", *Journal of Orthopaedic Research*, 1999; 17:130-138.

Bursac, "Collagen Network Contributions to Structure-Function Relationships in Cartilaginous Tissues in Compression" (Dissertation), Boston University College of Engineering, 2002.

Gooch et al., "IGF-I and Mechanical Environment Interact to Modulate Engineered Cartilage Development", *Biochemical and Biophysical Research Communications*, 2001; 286:909-915.

Pei et al., "Growth Factors for Sequential Cellular De- and Redifferentiation in Tissue Engineering", *Biochemical and Biophysical Research Communications*, 2002; 294:149-154.

Obradovic et al., "Integration of Engineered Cartilage", *Journal of Orthopaedic Research*, 19:1089-1097, 2001.

Schaefer et al., "Tissue Engineered Composites for the Repair of Large Osteochondral Defects", *Arthritis & Rheumatism*, 46(9): 2524-2534 (2002).

Pei et al., "Bioreactors Mediate the Effectiveness of Tissue Engineering Scaffolds", *The FASEB Journal*, 16:1691-1694, published online (Aug. 7, 2002), 10.1096/fj.02-0083fje.

Madry et al., "Gene Transfer of a Human Insulin-like Growth Factor I cDNA Enhances Tissue Engineering of Cartilage", *Human Gene Therapy*, 13: 1621-1630 (Sep. 1, 2002).

Pearson et al. (eds.), *American Association of Tissue Banks, Standards for Tissue Banking*, 2008 (12th ed.), pp. 53-56, 86-88.

Ornitz et al., "Protein Family Review: Fibroblast Growth Factors", *Genome Biology* (2001) 2(3): reviews 3005.1-3005.12, available at <http://genomebiology.com/2001/2/3/reviews/3005.1>.

Loeser et al., "Basic Fibroblast Growth Factor Inhibits the Anabolic Activity of Insulin-like Growth Factor 1 and Osteogenic Protein 1 in Adult Human Articular Chondrocytes", *Arthritis & Rheumatism*, vol. 52, No. 12 (Dec. 2005), pp. 3910-3917.

Kato et al., "Fibroblast Growth Factor is an Inhibitor of Chondrocyte Terminal Differentiation", *Journal of Biological Chemistry*, vol. 265, No. 10 (Apr. 5, 1990) pp. 5903-5909.

- Andrés et al., "A Pro-Inflammatory Signature Mediates FGF2-induced Angiogenesis", *Journal of Cellular and Molecular Medicine*, (Jun. 28, 2008), available at <http://www.ncbi.nlm.nih.gov/pubmed/18624773>.
- Burger et al., "Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells", *Blood*, vol. 100, No. 10 (Nov. 15, 2002) 3527-35.
- Baird, "Fibroblast growth factors: activities and significance of non-neurotrophin neurotrophic growth factors", *Current Opinions in Neurobiology*, (1994) 4:78-86.
- Mazué et al., "Preclinical and Clinical Studies with Recombinant Human Basic Fibroblast Growth Factor", *Annals New York Academy of Sciences*, (1991) 329-340.
- Aviles et al., "Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2)", *British Journal of Pharmacology* (2003) 140: 637-646.
- Nolan et al., "Living Bone Grafts", *BMJ*, vol. 304, Jun. 13, 1992, pp. 1520 and 1521.
- Stone et al., "One-Step American Technique of Articular Cartilage Paste Grafting to Traumatic and Arthritic Defects in the Knee Joint (2-7 Years Follow-Up)", downloaded from <http://web.archive.org/web/20041205005845/http://www.stoneclinic.com/onestep.thm>; published Dec. 5, 2004.
- Feczko et al., "Experimental Results of Donor Site Filling for Autologous Osteochondral Mosaicplasty", *Arthroscopy: The Journal of Arthroscopic and Related Surgery*, vol. 19, No. 7 (Sep. 2003), pp. 755-761.
- Nettles et al., "In Situ Crosslinkable Hyaluronan For Articular Cartilage Repair", 50th Annual Meeting of the Orthopaedic Research Society, Paper No. 0202 (Mar. 2004).
- Nettles et al., "Photocrosslinkable Hyaluronan as a Scaffold for Articular Cartilage Repair", *Annals of Biomedical Engineering*, vol. 32, No. 3, Mar. 2004, pp. 391-397.
- Peretti et al., "Cell-Based Bonding of Articular Cartilage: An Extended Study", *Journal of Biomedical Materials Research*, 64A, 2003, pp. 517-524.
- Bugbee, "Fresh Osteochondral Allografting", *Operative Techniques in Sports Medicine*, Apr. 2000, vol. 8, No. 2, pp. 158-162.
- Verbruggen et al., "Repair Function in Organ Cultured Human Cartilage. Replacement of Enzymatically Removed Proteoglycans During Longterm Organ Culture", *The Journal of Rheumatology*, 12:4, (1985), pp. 665-674.
- Peretti et al., "Cell-based Tissue-Engineered Allogeneic Implant for Cartilage Repair" *Tissue Engineering*, 2000, vol. 6. No. 5, pp. 567-576.
- Jackson et al., "Cartilage Substitute: Overview of Basic Science & Treatment Options", *Journal of American Academy of Orthopaedic Surgeons*, vol. 9, Jan./Feb. 2001, pp. 37-52.
- Glowacki, Julie, "Engineered Cartilage, Bone, Joints and Menisci-Potential for Temporomandibular Joint Reconstruction", *Cells Tissues Organs*, vol. 169, Issue 3, 2001, pp. 302-308.
- Peretti et al., "A Biomedical Analysis of an Engineered Cell-Scaffold Implant for Cartilage Repair", *Annals of Plastic Surgery*, 2001, vol. 46, No. 5, pp. 533-537.
- Peretti et al., "Biomechanical Analysis of a Chondrocyte-Based Repair Model of Articular Cartilage", *Tissue Engineering*, Aug. 1, 1999, vol. 5. No. 4, pp. 317-326.
- Non-Final Office Action mailed Apr. 15, 2010 in connection with U.S. Appl. No. 11/657,042.
- International Preliminary Report on Patentability for PCT/US2009/001459, mailed on May 12, 2010.
- Final Office Action mailed Mar. 22, 2010 in connection with U.S. Appl. No. 12/010,984.
- Search Report and Written Opinion for International Patent Application No. PCT/US2004/010957, issued on Nov. 1, 2004.
- International Preliminary Report on Patentability for International Patent Application No. PCT/US2004/010957, issued on Nov. 18, 2005.
- Search Report and Written Opinion for International Patent Application No. PCT/US2005/030610, issued on Apr. 7, 2006.
- International Preliminary Report on Patentability for International Patent Application No. PCT/US2005/030610, issued on Feb. 26, 2008.
- Search Report and Written Opinion for International Patent Application No. PCT/US2005/036878, issued on Sep. 21, 2006.
- International Preliminary Report on Patentability for International Patent Application No. PCT/US2005/036878, issued on Apr. 17, 2007.
- Search Report and Written Opinion for International Patent Application No. PCT/US2005/008798, issued on Jun. 19, 2006.
- International Preliminary Report on Patentability for International Patent Application No. PCT/US2005/008798, issued on Nov. 1, 2006.
- Search Report and Written Opinion for International Patent Application No. PCT/US2004/010956, issued on Oct. 28, 2005.
- International Preliminary Report on Patentability for International Patent Application No. PCT/US2004/010956, issued on Nov. 18, 2005.
- Search Report and Written Opinion for International Patent Application No. PCT/US2005/051796, issued on Jun. 23, 2009.
- International Preliminary Report on Patentability for International Patent Application No. PCT/US2008/051796, issued on Jul. 28, 2009.
- Search Report and Written Opinion for International Patent Application No. PCT/US2008/085522, issued on Jul. 6, 2009.
- Search Report and Written Opinion for International Patent Application No. PCT/US2009/001459, issued on Jul. 6, 2009.
- Non-Final Office Action mailed Apr. 15, 2010 in connection with U.S. Appl. No. 12/079,629.
- Non-Final Office Action mailed Apr. 12, 2010 in connection with U.S. Appl. No. 12/191,490.
- Non-Final Office Action mailed Apr. 26, 2010 in connection with U.S. Appl. No. 12/147,042.
- Matsuda et al. (1995) In Vivo Chondrogenesis in Collagen Sponge Sandwiched by Perichondrium. *J. Biomater. Sci. Polymer Ed.*, vol. 7, No. 3, pp. 221-229.
- Fujisato et al. (1996) Effect of basic fibroblast growth factor on cartilage regeneration in chondrocyte-seeded collagen sponge scaffold. *Biomaterials*, vol. 17, No. 2, pp. 155-162.
- Zhang, Jiandong et al., (1991) Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 Beta. *Proc Natl Acad Sci. USA* 88(8):3446-3450.
- Zhu, Hengyi et al., (1995) Glu-96 of basic fibroblast growth factor is essential for high affinity receptor binding. *Journal Of Biological Chemistry* 270(37):21869-21874.
- Zhu, Hengyi et al., (1997) Analysis of high-affinity binding determinants in the receptor binding epitope of basic fibroblast growth factor. *Protein Engineering* 10(4):417-421.
- Carr, M. E. Jr. and Alving, B. M. (1995) Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. *Blood Coag. Fibrinol.* 6(6):567-573.
- Carr, Marcus E. (1988) Fibrin formed in plasma is composed of fibers more massive than those formed from purified fibrinogen. *Thromb. Haemost.* 59(3):535-539.
- Cook, James L. et al., (2003) Biocompatibility of three-dimensional chondrocyte grafts in large tibial defects of rabbits. *Am J Vet Res.* 64(1):12-20.
- Gao, Jizong et al. (2002) Repair of osteochondral defect with tissue-engineered two-phase composite material of injectable calcium phosphate and hyaluronan sponge, *Tissue Engin.* 13(5):827-837.
- Gruber, Reinhard et al., (2002) Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes. *Clin Oral Implants Res.* 13(5):529-535.
- Haisch, A. et al., (2000) Preparation of a pure autologous biodegradable fibrin matrix for tissue engineering. *Med Biol Eng Comput.* 38(6):686-689.
- Itokazu, M. et al., (1997) The sustained release of antibiotic from freeze-dried fibrin-antibiotic compound and efficacies in a rat model of osteomyelitis. *Infection* 25(6):359-363.
- Sims, C. Derek et al., (1998) Tissue engineered neocartilage using plasma derived polymer substrates and chondrocytes. *Plastic & Recon. Surg.* 101(6):1580-1585.
- "Young's Modulus." Entry on <http://en.wikipedia.org>. accessed Oct. 27, 2005. 3 pages.

- Bradford, Marion M. (1976) A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. *Analytical Biochemistry* 72(1-2):248-254.
- Atala et al. (1993) Injectable alginate seeded with chondrocytes as a potential treatment for vesicoureteral reflux. *J. of Urology* 150(2 Pt 2):745-7.
- Temenoff et al., "Review: Tissue engineering for regeneration of articular cartilage", *Biomaterials* 21 (2000) pp. 431-440.
- Hunziker, "Articular cartilage repair: are the intrinsic biological constraints undermining this process insuperable?", *Osteoarthritis and Cartilage* 7 (1999) pp. 15-28.
- Final Office Action for U.S. Appl. No. 11/081,103, mailed Aug. 11, 2010.
- Non-Final Office Action for U.S. Appl. No. 12/010,984, mailed Aug. 16, 2010.
- U.S. Appl. No. 12/881,988, filed Sep. 14, 2010.
- Search Report and Written Opinion for International Patent Application No. PCT/US2010/085522, issued Jan. 14, 2010.
- U.S. Appl. No. 12/924,132, filed Sep. 21, 2010.
- U.S. Appl. No. 13/025,722, filed Feb. 11, 2011.
- Non-final Office Action with regard to U.S. Appl. No. 12/924,132, mailed Mar. 1, 2011.
- Non-final Office Action with regard to U.S. Appl. No. 12/381,072, mailed Jan. 20, 2011.
- Guilak, Farshid; "Functional Tissue Engineering: The Role of Biomechanics in Articular Cartilage Repair", *Clinical Orthopaedics and Related Research*, No. 391 S, pp. S295-S305, (c) 2001 Lippincott Williams & Wilkins, Inc., (11 pages).
- Spangenberg, Kimberly, M., et al. "Histomorphometric Analysis of a Cell-Based Model of Cartilage Repair", *Tissue Engineering*, vol. 8, No. 5, 2002, (8 pages).
- Peretti et al., "In Vitro Bonding of Pre-seeded Chondrocyte", *Sport Sciences for Health*, May 1, 2007, vol. 2, No. 1, pp. 29-33.
- Peretti et al., "Bonding of Cartilage Matrices with Cultured Chondrocytes: An Experiential Model", *Journal of Orthopedic Research*, Jan. 1998, vol. 16, No. 1, pp. 89-95.
- Hunziker, "Articular Cartilage Repair: Basic Science and Clinical Progress. A Review of the Current Status and Prospects", *Osteoarthritis and Cartilage* 2001, vol. 10, No. 6, pp. 432-463.
- Chen et al., "Repair of Articular Cartilage Defects: Part I. Basic Science of Cartilage Healing", *The American Journal of Orthopaedics*, Jan. 1999, pp. 31-33.
- Chen et al., "Repair of Articular Cartilage Defects: Part II. Treatment Options", *The American Journal of Orthopaedics*, Feb. 1999, pp. 88-96.
- Buckwalter, "Articular Cartilage Injuries", *Clinical Orthopaedics and Related Research*, 2002, No. 402, pp. 21-37.
- Nixon et al., "New Horizons in Articular Cartilage Repair", *Proceedings of the Annual Convention of the AAEP*, 2001, vol. 47, pp. 217-226.
- Tsumaki et al. "Role of CDMP-1 in Skeletal Morphogenesis: Promotion of Mesenchymal Cell Recruitment and Chondrocyte Differentiation", *J. Cell Biol.*, Jan. 1999, vol. 144, No. 1, 161-173.
- Trzeciak et al., "Evaluation of Cartilage Reconstruction by Means of Autologous Chondrocyte Versus Periosteal Graft Transplantation: An Animal Study", *Transplantation Proceedings*, vol. 38 (2006), pp. 305-311.
- Brighton et al., "Articular Cartilage Preservation and Storage-I. Application of Tissue Culture Techniques to the Storage of Viable Articular Cartilage", *Arthritis and Rheumatism*, vol. 22, No. 10 (Oct. 1979), pp. 1093-1101.
- Mahadev et al., "Autogenous Osteochondral Morselised Grafts for Full Thickness Osteochondral Defects in the Knee Joints of Pigs", *Singapore Medical Journal*, 2001, vol. 42(9), pp. 410-416.
- Hunziker, "Articular Cartilage Structure in Humans and Experimental Animals", *Articular Cartilage and Osteoarthritis*, Raven Press, ed., 2001, pp. 183-199.
- Giroto et al., "Tissue-specific gene expression in chondrocytes grown on three-dimensional hyaluronic acid scaffolds", *Biomaterials*, vol. 24 (2003), pp. 3265-3275.
- Gertzman et al., "A pilot study evaluating sodium hyaluronate as a carrier for freeze-dried demineralized bone powder", *Cell and Tissue Banking*, vol. 2, 2001, pp. 87-94.
- Diduch et al., "Joint Repair: Treatment Options for Articular Cartilage Injury" *Orthopedic Technology Review* (2002) 4:24-27.
- Gilbert, et al., "Decellularization of Tissues and Organs", *Biomaterials* (2006) 27:3675-3683.
- OsteoSponge product information, Bacterin International Inc., May 2005.
- <http://www.stoneclinic.com/articularcartilagepastegrafting> (Copyright 2009).
- <http://www.technobusiness-solutions.com/article-lyophilization1.html> (published Feb. 12, 2002).
- Crescenzi et al., "Hyaluron Linear and Crosslinked Derivatives as Potential/Actual Biomaterials", in *Hyaluronan* (2002), vol. 1 (Chemical, Biochemical and Biological Aspects), J. F. Kennedy et al., Ed., pp. 261-268.
- Michielen et al., "Novel Biomaterials Based on Cross-linked Hyaluronon: Structural Investigations", in *Hyaluronan* (2002), vol. 1 (Chemical, Biochemical and Biological Aspects), J. F. Kennedy et al., Ed., pp. 269-276.
- U.S. Appl. No. 12/147,042, based on U.S. Patent No. 7,067,123, filed Jun. 26, 2008, entitled: "Novel Glue for Cartilage Repair".
- Non-final Office Action mailed Aug. 19, 2009 in connection with U.S. Appl. No. 12/147,042.
- Non-final Office Action mailed Apr. 19, 2007 in connection with U.S. Appl. No. 11/151,270.
- Final Office Action mailed Oct. 9, 2007 in connection with U.S. Appl. No. 11/151,270.
- Advisory Action mailed Dec. 27, 2007 in connection with U.S. Appl. No. 11/151,270.
- Non-final Office Action mailed Jul. 9, 2008 in connection with U.S. Appl. No. 11/151,270.
- Non-final Office Action mailed Nov. 5, 2004 in connection with U.S. Appl. No. 10/438,883.
- Non-final Office Action mailed May 3, 2005 in connection with U.S. Appl. No. 10/438,883.
- A final Office Action mailed Oct. 18, 2005 in connection with U.S. Appl. No. 10/438,883.
- Non-final Office Action mailed Feb. 6, 2007 in connection with U.S. Appl. No. 10/438,883.
- A Communication mailed Oct. 9, 2007 in connection with U.S. Appl. No. 10/438,883.
- Non-final Office Action mailed Nov. 12, 2008 in connection with U.S. Appl. No. 10/438,883.
- Non-final Office Action mailed Feb. 7, 2008 in connection with U.S. Appl. No. 10/815,778.
- A final Office Action mailed Nov. 13, 2008 in connection with U.S. Appl. No. 10/815,778.
- Non-final Office Action mailed Jul. 2, 2009 in connection with U.S. Appl. No. 10/815,778.
- A final Office Action mailed Mar. 15, 2010 in connection with U.S. Appl. No. 10/815,778.
- Non-final Office Action mailed Feb. 20, 2007 in connection with U.S. Appl. No. 10/960,960.
- A final Office Action mailed Sep. 28, 2007 in connection with U.S. Appl. No. 10/960,960.
- Non-final Office Action mailed May 18, 2009 in connection with U.S. Appl. No. 11/657,042.
- A final Office Action mailed Dec. 28, 2009 in connection with U.S. Appl. No. 11/657,042.
- Non-final Office Action mailed Jan. 14, 2010 in connection with U.S. Appl. No. 11/081,103.
- Non-final Office Action mailed Jul. 22, 2009 in connection with U.S. Appl. No. 12/010,984.
- Non-final Office Action mailed Oct. 5, 2005 in connection with U.S. Appl. No. 10/424,765.
- Non-final Office Action mailed Dec. 18, 2007 in connection with U.S. Appl. No. 11/081,103.
- A final Office Action mailed Sep. 19, 2008 in connection with U.S. Appl. No. 11/081,103.
- Non-final Office Action mailed Jun. 3, 2009 in connection with U.S. Appl. No. 11/081,103.



- Abraham, Judith A. et al., (1986) Human Basic Fibroblast Growth Factor: Nucleotide Sequence And Genomic Organization. *EMBO Journal* 5(10):2523-2528.
- Agrawal, Sudhir et al., (1991) Pharmacokinetics, Biodistribution, And Stability Of Oligodeoxynucleotide Phosphorothioates In Mice. *Proc Natl Acad Sci. USA* 88(17):7595-7599.
- Arakawa, Tsutomu et al., (1993) Production and Characterization of an Analog of Acidic Fibroblast Growth Factor With Enhanced Stability and Biological Activity. *Protein Engineering* 6(5):541-546.
- Bailly, Karine et al., (2000) Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor. *FASEB Journal* 14(2):333-343.
- Bange, Johannes et al., (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 allele. *Cancer Research* 62(3):840-846.
- Bork, Peer (2000) Powers and pitfalls in sequence analysis: The 70% hurdle. *Genome Res.* 10(4):398-400.
- Bork, Peer and Bairoch, Amnon (1996) Go hunting in sequence databases but watch out for the traps. *Trends in Genetics* 12(10):425-427.
- Brenner, Steven E. (1999) Errors in genome annotation. *Trends in Genetics* 15(4):132-133.
- Cappellen, David et al., (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. *Nature Genetics* 23(1):18-20.
- Chusho, Hideki et al., (2001) Dwarfism and early death in mice lacking C-type Natriuretic Peptide. *Proc Natl Acad Sci.* 98(7):4016-4021.
- Coughlin, Shaun R. et al., (1988) Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo. *J Biol Chem.* 263(2):988-993.
- Dell'Accio, Francesco et al., (2001) Molecular markers predictive of the capacity of expanded human articular chondrocytes to form stable cartilage in vivo, *Arthritis Rheum.* 44(7):1608-19.
- Doerks, Tobias et al., (1998) Protein annotation: detective work for function prediction. *Trends Genet.* 14(6):248-250.
- Dvorakova, Dana et al., (2001) Changes in the expression of FGFR3 in patients with chronic myeloid leukaemia receiving transplants of allogeneic peripheral blood stem cells *British Journal Haematology* 13(3):832-835.
- Eriksson, A. Elisabeth et al., (1991) Three-dimensional structure of human basic fibroblast growth factor. *Proc. Natl. Acad. Sci. USA* 88:3441-3445 (XP002936511).
- Ezzat Shereen et al., (2002) Targeted expression of A Human pituitary tumor-derived isoform of FGF Receptor-4 Recapitulates Pituitary Tumorigenesis. *Journal of Clinical Investigation* 109(1):69-77.
- Faham, Salem et al., (1998) Diversity does make a difference: fibroblast growth factor—Heparin interactions. *Curr Opin Struct Biol* 8(5):578-586.
- Fingl, Edward and Woodbury, Dixon M. (1975) General Principles. In: *The Pharmacological Basis of Therapeutics*. Fifth edition. Goodman, Louis S. and Gilman, Alfred editors. 1:1-45.
- Gargiulo, B. J. et al., (2002) Phenotypic modulation of human articular chondrocytes by bistratene A. *Eur Cell Mater.* 3:9-18.
- Givol, David and Yayon, Avner (1992) Complexity of FGF receptors: genetic basis for structural diversity and functional specificity *FASEB J.* 6(15):3362-3369.
- Hecht, H. J. et al., (2000) Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor-and heparin-binding interfaces. *Acta Cryst.* D57:378-384.
- Johnson, Daniel E. and Williams, Lewis T. (1993) Structural and functional diversity in the FGF receptor multigene family. *Adv Cancer Res.* 60:1-41.
- Kirikoshi, Hiroyuki et al., (2000) Molecular cloning and characterization of Human FGF-20 on chromosome 8p21.3-p22. *Biochem Biophys Res Commun.* 274(2):337-343.
- Kuroda, S. et al., (1999) Anabolic effect of aminoterminally truncated Fibroblast Growth Factor 4 (FGF4) on bone. *Bone* 25(4):431-437.
- Nakatake, Yuhki et al., (2001) Identification of a novel fibroblast growth factor, FGF-22, preferentially expressed in the inner root sheath of the hair follicle. *Biochim Biophys Acta.* 1517(3):460-463.
- Ngo, J. Thomas et al., (1994) Computational complexity, protein structure prediction, and the Levithal Paradox. In: *The Protein Folding Problem and Tertiary Structure Prediction*. K. Merz Jr. and S. Le Grand, Editors. 433-506 see also table of contents.
- Nishimura, Tetsuya et al., (2000) Identification of a Novel FGF, FGF-21, Preferentially Expressed In The Liver. *Biochim Biophys Acta* 1492(1):203-206.
- Okada-Ban, Mai et al., (2000) Fibroblast growth factor-2. *International Journal of Biochemistry & Cell Biology* 32 (3):263-267.
- Olsen, Shaun K. (2003) Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. *J Biol Chem.* 278(36):34226-34236.
- Ornitz, David M. et al., (1996) Receptor specificity of the fibroblast growth factor family. *J Biol Chem.* 271(25):5292-7.
- Ornitz, David M. (2000) FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. *Bio Essays* 22:108-112.
- Pellegrini, Luca et al., (2000) Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. *Nature* 407(6807):1029-1034.
- Pillai, Omathanu and Panchagnula, Ramesh (2001) Polymers in drug delivery. *Curr Opin Chem Biol* 5 (4):447-451.
- Plotnikov, Alexander N. et al., (1999) Structural basis for FGF receptor dimerization and activation. *Cell* 98 (5):641-650.
- Plotnikov, Alexander N. et al., (2000) Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. *Cell* 101(4): 413-424.
- Sahni, Malika et al., (1999) FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway *Genes Devel.* 13(11):1361-1366.
- Schlessinger, Joseph et al., (2000) Crystal structure of a ternary FGF-FGFR-1 Heparin complex reveals a dual role for heparin in FGFR binding and dimerization. *Mol Cell* 6(3):743-750.
- Schmal, H. et al., (2007) bFGF influences human articular chondrocyte differentiation. *Cytotherapy* 9(2):184-93.
- Seno, Masaharu et al., (1990) Carboxyl-terminal structure of basic fibroblast growth factor significantly contributes to its affinity for Heparin. *Eur J Biochem.* 188:239-245.
- Shao, Zhang-Qiang et al., (2006) Effects of intramyocardial administration of slow-release basic fibroblast growth factor on angiogenesis and ventricular remodeling in a rat infarct model. *Circ. J.* 70(4):471-477.
- Skolnik, Jeffrey and Fetrow, Jacquelyn S. (2000) From genes to protein structure and function: novel applications of computational approaches in the genomic era. *Trends BioTechnol.* 18(1):34-39.
- Sleeman, Matthew et al., (2001) Identification of a new fibroblast growth factor receptor, FGFR5. *Gene* 271 (2):171-182.
- Smith, Temple and Zhang, Xiaolin (1997) The challenges of genome sequence annotation or The devil is in the details. *Nat Biotechnol.* 15(12):1222-1223.
- Springer, Barry A. et al., (1994) Identification and Concerted Function of Two Receptors Binding Surfaces on Basic Fibroblast Growth Factor Required for Mitogenesis. *The Journal of Biological Chemistry* 269(43):26879-26884.
- Stauber, Deborah J. et al., (2000) Structural interactions of fibroblast growth factor receptor with its ligands. *Proc Natl Acad Sci USA* 97(1):49-54.
- Vajo, Zoltan et al., (2000) The Molecular and Genetic Basis of Fibroblast Growth Factor Receptor 3 Disorders: The Achondroplasia Family of Skeletal Dysplasias, Muenke Craniosynostosis, and Crouzon Syndrome with Acanthosis Nigricans. *Endocrine Rev.* 21(1):23-39.
- Wells, James A. (1990) Additivity of mutational effects in proteins. *Biochemistry* 29(37):8509-8517.
- Yamashita, Tetsuo et al., (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. *Biochemical and Biophysical Research Communications* 277(2):494-498.
- Yayon, Avner et al., (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. *Cell* 64(4):841-848.
- Yee, Cindy J. et al., (2000) Analysis of fibroblast growth factor receptor 3 S249C mutation in cervical carcinoma. *Journal of the National Cancer Institute* 92(22):1848-1849.

Non-final Office Action for U.S. Appl. No. 12/322,996, mailed Apr. 4, 2011.

Non-final Office Action for U.S. Appl. No. 12/043,001, mailed May 11, 2011.

Supplemental Search report for European Patent Application No. 05728956.3, dated May 2, 2011.

Communication pursuant to Article 94(3) EPC for European Patent Application No. 08 782 728.3, dated Aug. 9, 2011.

International Preliminary Report on Patentability for International Patent Application No. PCT/US2010/000108, mailed Jul. 28, 2011.

First Action Interview Pilot Pre-Interview Communication for U.S. Appl. No. 12/931,427, mailed Aug. 19, 2011.

Non-final Office Action for U.S. Appl. No. 12/179,034, mailed Jun. 29, 2011.

Final Office Action for U.S. Appl. No. 12/381,072, mailed Jun. 27, 2011.

Non-final Office Action for U.S. Appl. No. 12/924,132, mailed Jul. 18, 2011.

Cheng, et al, "Chondrogenic Differentiation of Adipose-Derived Adult Stem Cells by a Porous Scaffold Derived from Native Articular Cartilage Extracellular Matrix", *Tissue Engineering: Part A*, vol. 15, No. 2. (2009), pp. 231-241.

Lin et al. "The Chondrocyte: Biology and Clinical Application", *Tissue Engineering*, vol. 12, No. 7, (2006), pp. 1971-1984.

Umlauf et al., "Cartilage biology, pathology, and repair", *Cell. Mol. Life Sci.*, vol. 67, (2010), pp. 4197-4211.

First Action Interview Pilot Program Pre-Interview Communication for U.S. Appl. No. 12/696,366, mailed Oct. 13, 2011.


Non-final Office Action for U.S. Appl. No. 12/881,988, mailed Oct. 26, 2011.

Non-final Office Action for U.S. Appl. No. 11/081,103, mailed Nov. 28, 2011.


Non-final Office Action for U.S. Appl. No. 12/508,892, mailed Dec. 7, 2011.

Sedgwick et al., "Studies into the influence of carrageenan-induced inflammation on articular cartilage degradation using implantation into air pouches", *British Journal of Experimental Pathology*, vol. 66, (1985), pp. 445-453.


\* cited by examiner



**Fig. 1**



**Fig. 2**



**Fig. 3**

## GLUE FOR CARTILAGE REPAIR

**Matter enclosed in heavy brackets [ ] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue.**

*CROSS-REFERENCE TO RELATED APPLICATIONS*

*More than one reissue application has been filed for the reissue of U.S. Pat. No. 7,067,123, issued Jun. 27, 2006, said reissue applications being U.S. application Ser. No. Re. 12/147,042, filed Jun. 26, 2008, now U.S. Pat. No. Re. 42,208, and the present application, which is a continuation reissue application of U.S. application Ser. No. Re. 12/147,042.*

[RELATED APPLICATIONS]

[There is no related application.]

1. Field of Invention

The present invention is generally directed toward an implant and is more specifically directed toward a paste or gel implant material for a cartilage defect.

2. Background of the Invention

Articular cartilage injury and degeneration present medical problems to the general population which are addressed by orthopedic surgeons. Every year in the United States, over 500,000 arthroplastic or joint repair procedures are performed. These include approximately 125,000 total hip and 150,000 total knee arthroplasties and over 41,000 open arthroscopic procedures to repair cartilaginous defects of the knee.

In the knee joint, the articular cartilage tissue forms a lining which faces the joint cavity on one side and is linked to the subchondral bone plate by a narrow layer of calcified cartilage tissue on the other. Articular cartilage (hyaline cartilage) consists primarily of extracellular matrix with a sparse population of chondrocytes distributed throughout the tissue. Articular cartilage is composed of chondrocytes, type II collagen fibril network, proteoglycans and water. Active chondrocytes are unique in that they have a relatively low turnover rate and are sparsely distributed within the surrounding matrix. The collagens give the tissue its form and tensile strength and the interaction of proteoglycans with water give the tissue its stiffness to compression, resilience and durability. The hyaline cartilage provides a low friction bearing surface over the bony parts of the joint. If the lining becomes worn or damaged resulting in lesions, joint movement may be painful or severely restricted. Whereas damaged bone typically can regenerate successfully, hyaline cartilage regeneration is quite limited because of its limited regenerative and reparative abilities.

Articular cartilage lesions generally do not heal, or heal only partially under certain biological conditions due to the lack of nerves, blood vessels and a lymphatic system. The limited reparative capabilities of hyaline cartilage usually results in the generation of repair tissue that lacks the structure and biomechanical properties of normal cartilage. Generally, the healing of the defect results in a fibrocartilaginous repair tissue that lacks the structure and biomedical properties of hyaline cartilage and degrades over the course of time. Articular cartilage lesions are frequently associated with disability and with symptoms such as joint pain, locking phenomena and reduced or disturbed function. These lesions are difficult to treat because of the distinctive structure and func-

tion of hyaline cartilage. Such lesions are believed to progress to severe forms of osteoarthritis. Osteoarthritis is the leading cause of disability and impairment in middle-aged and older individuals, entailing significant economic, social and psychological costs. Each year, osteoarthritis accounts for as many as 39 million physician visits and more than 500,000 hospitalizations. By the year 2020, arthritis is expected to affect almost 60 million persons in the United States and to limit the activity of 11.6 million persons.

There are many current therapeutic methods being used. None of these therapies has resulted in the successful regeneration of hyaline-like tissue that withstands normal joint loading and activity over prolonged periods. Currently, the techniques most widely utilized clinically for cartilage defects and degeneration are not articular cartilage substitution procedures, but rather lavage, arthroscopic debridement, and repair stimulation. The direct transplantation of cells or tissue into a defect and the replacement of the defect with biologic or synthetic substitutions presently accounts for only a small percentage of surgical interventions. The optimum surgical goal is to replace the defects with cartilage-like substitutes so as to provide pain relief, reduce effusions and inflammation, restore function, reduce disability and postpone or alleviate the need for prosthetic replacement.

Lavage and arthroscopic debridement involve irrigation of the joint with solutions of sodium chloride, Ringer or Ringer and lactate. The temporary pain relief is believed to result from removing degenerative cartilage debris, proteolytic enzymes and inflammatory mediators. These techniques provide temporary pain relief, but have little or no potential for further healing.

Repair stimulation is conducted by means of drilling, abrasion arthroplasty or microfracture. Penetration into the subchondral bone induces bleeding and fibrin clot formation which promotes initial repair, however, the tissue formed is fibrous in nature and not durable. Pain relief is temporary as the tissue exhibits degeneration, loss of resilience, stiffness and wear characteristics over time.

The periosteum and perichondrium have been shown to contain mesenchymal progenitor cells capable of differentiation and proliferation. They have been used as grafts in both animal and human models to repair articular defects. Few patients over 40 years of age have obtained good clinical results, which most likely reflects the decreasing population of osteochondral progenitor cells with increasing age. There have also been problems with adhesion and stability of the grafts, which result in their displacement or loss from the repair site.

Transplantation of cells grown in culture provides another method of introducing a new cell population into chondral and osteochondral defects. Carticel® is a commercial process to culture a patient's own cartilage cells for use in the repair of cartilage defects in the femoral condyle marketed by Genzyme Biosurgery in the United States and Europe. The procedure uses arthroscopy to take a biopsy from a healthy, less loaded area of articular cartilage. Enzymatic digestion of the harvested tissue releases the cells that are sent to a laboratory where they are grown for a period ranging from 2-5 weeks. Once cultivated, the cells are injected during a more open and extensive knee procedure into areas of defective cartilage where it is hoped that they will facilitate the repair of damaged tissue. An autologous periosteal flap with cambium layer is used to seal the transplanted cells in place and act as a mechanical barrier. Fibrin glue is used to seal the edges of the flap. This technique preserves the subchondral bone plate and has reported a high success rate. Proponents of this procedure report that it produces satisfactory results, including

the ability to return to demanding physical activities, in more than 90% of patients and that biopsy specimens of the tissue in the graft sites show hyaline-like cartilage repair. More work is needed to assess the function and durability of the new tissue and determine whether it improves joint function and delays or prevents joint degeneration. As with the perichondrial graft, patient/donor age may compromise the success of this procedure as chondrocyte population decreases with increasing age. Disadvantages to this procedure include the need for two separate surgical procedures, potential damage to surrounding cartilage when the periosteal patch is sutured in place, the requirement of demanding microsurgical techniques, and the expensive cost of the procedure which is currently not covered by insurance.

Osteochondral transplantation or mosaicplasty involves excising all injured or unstable tissue from the articular defect and creating cylindrical holes in the base of the defect and underlying bone. These holes are filled with autologous cylindrical plugs of healthy cartilage and bone in a mosaic fashion. The osteochondral plugs are harvested from a lower weight-bearing area of lesser importance in the same joint. This technique, shown in Prior Art FIG. 2, can be performed as arthroscopic or open procedures. Reports of results of osteochondral plug autografts in a small number of patients indicate that they decrease pain and improve joint function, however, long-term results have not been reported. Factors that can compromise the results include donor site morbidity, effects of joint incongruity on the opposing surface of the donor site, damage to the chondrocytes at the articular margins of the donor and recipient sites during preparation and implantation, and collapse or settling of the graft over time. The limited availability of sites for harvest of osteochondral autografts restricts the use of this approach to treatment of relatively small articular defects and the healing of the chondral portion of the autograft to the adjacent articular cartilage remains a concern.

Transplantation of large allografts of bone and overlying articular cartilage is another treatment option that involves a greater area than is suitable for autologous cylindrical plugs, as well as for a non-contained defect. The advantages of osteochondral allografts are the potential to restore the anatomic contour of the joint, lack of morbidity related to graft harvesting, greater availability than autografts and the ability to prepare allografts in any size to reconstruct large defects. Clinical experience with fresh and frozen osteochondral allografts shows that these grafts can decrease joint pain, and that the osseous portion of an allograft can heal to the host bone and the chondral portion can function as an articular surface. Drawbacks associated with this methodology in the clinical situation include the scarcity of fresh donor material and problems connected with the handling and storage of frozen tissue. Fresh allografts carry the risk of immune response or disease transmission. Musculoskeletal Transplant Foundation (MTF) has preserved fresh allografts in a media that maintains a cell viability of 50% for 35 days for use as implants. Frozen allografts lack cell viability and have shown a decreased amount of proteoglycan content which contribute to deterioration of the tissue.

A number of patents in the prior art show the use of bone putty, pastes or gels to fill bone defects. U.S. Pat. No. 5,290,558 issued Mar. 1, 1994 discloses a flowable demineralized bone powder composition using an osteogenic bone powder with large particle size ranging from about 0.1 to about 1.2 cm. mixed with a low molecular weight polyhydroxy compound possessing from 2 to about 18 carbons including a

number of classes of different compounds such as monosaccharides, disaccharides, water dispersible oligosaccharides and polysaccharides.

A bone gel is disclosed in the U.S. Pat. No. 5,073,373 issued Dec. 17, 1991. Bone lamellae in the shape of threads or filaments retaining low molecular weight glycerol carrier are disclosed in U.S. Pat. Nos. 5,314,476 issued May 24, 1994 and 5,507,813 issued Apr. 16, 1996 and the tissue forms described in these patents are known commercially as the GRAFTON® Putty and Flex, respectively.

U.S. Pat. No. 5,356,629 issued Oct. 18, 1994 discloses making a rigid gel in the nature of a bone cement to fill defects in bone by mixing biocompatible particles, preferably polymethylmethacrylate coated with polyhydroxyethylmethacrylate in a matrix selected from a group which lists hyaluronic acid to obtain a molded semi-solid mass which can be suitably worked for implantation into bone. The hyaluronic acid can also be utilized in monomeric form or in polymeric form preferably having a molecular weight not greater than about one million Daltons. It is noted that the nonbioabsorbable material which can be used to form the biocompatible particles can be derived from xenograft bone, homologous bone, autogenous bone as well as other materials. The bioactive substance can also be an osteogenic agent such as demineralized bone powder, morselized cancellous bone, aspirated bone marrow and other autogenous bone sources. The average size of the particles employed is preferably about 0.1 to about 3.0 mm, more preferably about 0.2 to about 1.5 mm, and most preferably about 0.3 to about 1.0 mm. It is inferentially mentioned but not taught that particles having average sizes of about 7,000 to 8,000 microns, or even as small as about 100 to 700 microns can be used.

U.S. Pat. No. 4,172,128 issued Oct. 23, 1979 discloses a demineralized bone material mixed with a carrier to reconstruct tooth or bone material by adding a mucopolysaccharide to a mineralized bone colloidal material. The composition is formed from a demineralized coarsely ground bone material, which may be derived from human bones and teeth, dissolved in a solvent forming a colloidal solution to which is added a physiologically inert polyhydroxy compound such as mucopolysaccharide or polyuronic acid in an amount which causes orientation when hydrogen ions or polyvalent metal ions are added to form a gel. The gel will be flowable at elevated temperatures above 35° C. and will solidify when brought down to body temperature. Example 25 of the patent notes that mucopolysaccharides produce pronounced ionotropic effects and that hyaluronic acid is particularly responsible for spatial cross-linking.

U.S. Pat. No. 6,030,635 issued Feb. 29, 2000 and U.S. Pat. No. 6,437,018 issued Aug. 20, 2002 are directed toward a malleable bone putty and a flowable gel composition for application to a bone defect site to promote new bone growth at the site which utilize a new bone growth inducing compound of demineralized lyophilized allograft bone powder. The bone powder has a particle size ranging from about 100 to about 850 microns and is mixed in a high molecular weight hydrogel carrier which contains a sodium phosphate saline buffer.

The use of implants for cartilage defects is much more limited. Aside from the fresh allograft implants and autologous implants, U.S. Pat. No. 6,110,209 issued Nov. 5, 1998 shows the use an autologous articular cartilage cancerous bone paste to fill arthritic defects. The surgical technique is arthroscopic and includes debriding (shaving away loose or fragmented articular cartilage), followed by morselizing the base of the arthritic defect with an awl until bleeding occurs. An osteochondral graft is then harvested from the inner rim of

the intercondylar notch using a trephine. The graft is then morselized in a bone graft crusher, mixing the articular cartilage with the cancellous bone. The paste is then pushed into the defect and secured by the adhesive properties of the bleeding bone. The paste can also be mixed with a cartilage stimulating factor, a plurality of cells, or a biological glue. All patients are kept non-weight bearing for four weeks and used a continuous passive motion machine for six hours each night. Histologic appearance of the biopsies have mainly shown a mixture of fibrocartilage with hyaline cartilage. Concerns associated with this method are harvest site morbidity and availability, similar to the mosaicplasty method.

#### SUMMARY OF THE INVENTION

A cartilage implant material in paste or gel form for repairing articular cartilage defects is composed of milled allograft cartilage pieces in a bioabsorbable carrier. Autologous chondrocyte in an amount exceeding the number naturally occurring in hyaline cartilage for a mature adult between 20 and 55 years of age may also be applied to the matrix. Additives may be applied to the mixture in order to increase chondrocyte migration and proliferation. The implant material can support the addition of a variety of chondrogenic stimulating factors including, but not limited to growth factors (FGF-2, FGF-5, IGF-1, TGF- $\beta$ , BMP-2, BMP-7, PDGF, VEGF), human allogenic or autologous chondrocytes, human allogenic or autologous bone marrow cells, stem cells, demineralized bone matrix, insulin, insulin-like growth factor-1, transforming growth factor-B, interleukin-1 receptor antagonist, hepatocyte growth factor, platelet-derived growth factor, Indian hedgehog and parathyroid hormone-related peptide or bioactive glue.

The implant material is placed in the lesion area and may be sealed with a periosteum cap.

It is an object of the invention to provide an allograft implant material for joints which provides pain relief, restores normal function and will postpone or alleviate the need for prosthetic replacement.

It is also an object of the invention to provide a cartilage repair implant material which is easily placed in a defect area by the surgeon using an arthroscopic, minimally invasive technique.

It is further an object of the invention to provide an allograft implant material procedure which is applicable for both partial and full thickness lesions.

It is yet another object of the invention to provide an allograft implant material which facilitates growth of hyaline cartilage.

It is an additional object of the invention to provide implant paste and gel material formulations that satisfy surgical requirements and are made from donated human available allograft tissue, some of which would otherwise be considered waste and thrown away.

These and other objects, advantages, and novel features of the present invention will become apparent when considered with the teachings contained in the detailed disclosure along with the accompanying drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the anatomy of a knee joint with a lesion;  
 FIG. 2 shows a schematic mosaicplasty as known in the prior art; and  
 FIG. 3 shows a schematic perspective view of cartilage defect material placed in a defect site with an exploded periosteum cap.

#### DESCRIPTION OF THE INVENTION

The terms "tissue" is used in the general sense herein to mean any transplantable or implantable tissue, the survivability of which is improved by the methods described herein upon implantation. In particular, the overall durability and longevity of the implant are improved, and host-immune system mediated responses, are substantially eliminated.

The terms "transplant" and "implant" are used interchangeably to refer to tissue, material or cells (xenogeneic or allogeneic) which may be introduced into the body of a patient to replace or supplement the structure or function of the endogenous tissue.

The terms "autologous" and "autograft" refer to tissue or cells which originate with or are derived from the recipient, whereas the terms "allogeneic" and "allograft" refer to cells and tissue which originate with or are derived from a donor of the same species as the recipient. The terms "xenogeneic" and "xenograft" refer to cells or tissue which originates with or is derived from a species other than that of the recipient.

The term "gel" refers to a mixture of minced or milled pretreated allograft cartilage in a biocomposite carrier having a viscosity which is less than and is less rigid than a mixture of minced or milled pretreated allograft cartilage in a biocompatible carrier referred to by the terms "putty" or "paste" and contains less cartilage by weight than putty or paste.

The present invention is directed towards a cartilage repair material and method of treatment. The preferred embodiment and best mode of the invention is shown in FIG. 3. In the production of the invention, allograft hyaline cartilage is lyophilized reducing its water content and milled for ease in application.

After washes with sterile de-ionized (DI) water, the cartilage material was frozen at  $-20^{\circ}$  to  $-100^{\circ}$  C. preferably  $-70^{\circ}$  C. and lyophilized to reduce the water content within the range of about 0.1% to about 8.0%. The cartilage is frozen with liquid nitrogen and ground into particles.

A lesion or defect is removed by cutting a bore **50** or trimming a lesion in the implant area **100** and filling the bore **50** or lesion area with a milled cartilage mixture **20** of paste or gel consisting together with a biological carrier such as hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or polymers and one or more additives namely chondrogenic stimulating factors including, but not limited to growth factors (FGF-2, FGF-5, IGF-1, TGF- $\beta$ , BMP-2, BMP-7, PDGF, VEGF), human allogenic or autologous chondrocytes, human allogenic cells, human allogenic or autologous bone marrow cells, human allogenic or autologous stem cells, demineralized bone matrix, insulin, insulin-like growth factor-1, interleukin-1 receptor antagonist, hepatocyte growth factor, platelet-derived growth factor, Indian hedgehog and parathyroid hormone-related peptide.

Suitable organic glue material can be used to keep the viscous cartilage mixture **20** fixed in place in the implant area or to affix a periosteal cap **30** in place over the surrounding hyaline cartilage area **100**. Suitable organic glue material can be found commercially, such as for example; TISSEEL<sup>®</sup> or TISSUCOL<sup>®</sup> (fibrin based adhesive; Immuno AG, Austria), Adhesive Protein (Sigma Chemical, USA), and Dow Corning Medical Adhesive B (Dow Corning, USA).

#### EXAMPLE 1

A matrix of minced cartilage putty consisting of minced or milled allograft articular cartilage which has been lyophilized so that its water content ranges from 0.1% to 8.0% with a cartilage content ranging from 25% to 50% by weight is

mixed with a carrier of sodium hyaluronate solution (HA) (molecular weight ranging from  $7.0 \times 10^5$  to  $1.2 \times 10^6$ ) or any other bioabsorbable carrier such as hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or polymers, the carrier ranging from 75% to 50% by weight. The cartilage is milled to a size ranging from 0.01 mm to 1 mm. In gel form, the minced cartilage which has been lyophilized so that its water content ranges from 0.1% to 8.0% ranging from 15% to 30% by weight and the carrier ranges from 85% to 70% by weight. The particle size of the cartilage when milled is less than or equal to 1 mm dry in the previously stated range. The cartilage pieces can be processed to varying particle sizes and the HA or other carrier can have different viscosities depending on the desired consistency of the putty or paste. This cartilage matrix can be deposited into the cartilage defect arthroscopically and fit into the defect where it is held in place by its own viscosity, mixed with fibrin glue or covered with a periosteal or perichondrial flap, then sealed with biological glue. As with the first two matrices, this matrix can support the previously mentioned chondrogenic factors.

## EXAMPLE 2

A matrix of minced cartilage putty consisting of minced or milled allograft cartilage which has been lyophilized so that its water content ranges from 0.1% to 8.0% ranging from 25% to 50% by weight is mixed with a carrier of sodium hyaluronate solution (HA) ( $7.0 \times 10^5$  to  $1.2 \times 10^6$ ) or any other bioabsorbable carrier such as hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or polymers ranging from 75% to 50% by weight. In a gel form, the minced cartilage which has been lyophilized so that its water content ranges from 0.01% to 8.0% ranging from 15% to 30% by weight and the carrier ranges from 85% to 70% by weight. The particle size of the cartilage is less than or equal to 1 mm dry ranging from 0.01 mm to 1 mm. The cartilage pieces can be processed to varying particle sizes and the HA or carrier can have different viscosities depending on the desired consistency of the putty or paste. Autologous or allogenic cells which have been grown outside the patient are inserted by syringe into the matrix before, during or after deposit of the cartilage matrix into the defect area. Such cells include allogenic or autologous bone marrow cells, stem cells and chondrocyte cells. The cellular density of the cells preferably ranges from about  $1 \times 10^8$  to  $5 \times 10^8$  or from about 100 million to about 500 million cells per cc of putty or gel mixture. This composite material can be injected into the cartilage defect arthroscopically and fit into the defect where it is held in place by its own viscosity, or covered with a periosteal or perichondrial flap, then sealed with biological glue. As with the first matrix, this matrix can support the previously mentioned chondrogenic factors.

The operation of placing the cartilage composition in a cartilage defect, comprises (a) cutting a patient's tissue at a site of a cartilage defect to remove the diseased area of cartilage; (b) placing a mixture of milled allograft cartilage in a bioabsorbable carrier in the defect area; and (c) placing a periosteal cover over the mixture of the inserted milled allograft cartilage in a bioabsorbable carrier to contain the mixture in the defect area for a predetermined period of time to promote cartilage growth at the defect site. Alternate steps include the addition of growth factors, chondrocytes, bone marrow cells and stem cells.

The principles, preferred embodiments and modes of operation of the present invention have been described in the foregoing specification. However, the invention should not be

construed as limited to the particular embodiments which have been described above. Instead, the embodiments described here should be regarded as illustrative rather than restrictive.

What we claim is:

[1. A sterile allograft cartilage defect implant material for use in human beings comprising milled allograft cartilage pieces sized less than 1 mm and lyophilized so that their water content ranges from about 0.1% to about 8.0% in a bioabsorbable carrier.]

[2. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage ranges from about 25% to about 50% by weight and said carrier ranges from about 75% to about 50% by weight.]

[3. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage ranges from about 15% to about 30% by weight with the carrier ranging from about 85% to about 70% by weight.]

[4. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said carrier is sodium hyaluronate and its derivatives.]

[5. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said implant material includes a protein glue.]

[6. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said implant material includes the addition of autologous chondrocytes to achieve a concentration exceeding the concentration of chondrocytes naturally occurring in the patient.]

[7. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage is hyaline cartilage.]

[8. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage is fibrosus cartilage.]

[9. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage is hyaline and fibrosus cartilage.]

[10. A sterile allograft cartilage defect implant material claimed in claim 1 including an additive to said implant material consisting of one or more of a group consisting of growth factors, human allogenic cells, human allogenic bone marrow cells, human autologous bone marrow cells, human allogenic stem cells, human autologous stem cells, human demineralized bone matrix, and insulin.]

[11. A sterile cartilage repair material as claimed in claim 10 wherein said growth factors are one or more of a group consisting of FGF-2, FGF-5, IGF-1, TGF- $\beta$ , BMP-2, BMP-7, PDGF, VEGF.]

[12. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said carrier comprises one or more bioabsorbable carriers taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers.]

[13. A sterile cartilage defect implant material comprising milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers and allogenic chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage.]

[14. A sterile cartilage defect implant material as claimed in claim 13 wherein said allograft articular cartilage is hyaline cartilage.]

**[15.** A sterile allograft cartilage defect implant material as claimed in claim 13 wherein said milled cartilage is fibrous cartilage.]

**[16.** A sterile allograft cartilage defect implant material as claimed in claim 13 wherein said milled cartilage is hyaline and fibrous cartilage.]

**[17.** A sterile cartilage repair material as claimed in claim 13 wherein said implant material includes an additive consisting of one or more of a group consisting of growth factors, human allogenic cells, human allogenic bone marrow cells, human autologous bone marrow cells, human allogenic stem cells, human autologous stem cells, demineralized bone matrix, and insulin.]

**[18.** A sterile cartilage repair material as claimed in claim 17 wherein said growth factors are one or more of a group consisting of FGF-2, FGF-5, IGF-1, TGF- $\beta$ , BMP-2, BMP-7, PDGF, VEGF.]

**[19.** A sterile cartilage defect implant material as claimed in claim 13 wherein said milled cartilage ranges from about 25% to about 50% by weight and said carrier ranges from about 75% to about 50% by weight.]

**[20.** A sterile cartilage defect implant material as claimed in claim 13 wherein said milled cartilage ranges from about 15% to about 30% by weight with the carrier ranging from about 85% to about 70% by weight.]

**[21.** A sterile cartilage defect implant material comprising lyophilized milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers and autologous bone marrow cells in an amount exceeding the natural occurrence of same in a patient being treated.]

**[22.** A sterile cartilage defect repair material as claimed in claim 21 including an additive in said implant material which consists of one or more of a group consisting of growth factors, human allogenic cells, autologous chondrocytes, demineralized bone matrix, and insulin.]

**[23.** A sterile cartilage repair material as claimed in claim 22 wherein said growth factors are one or more of a group consisting of FGF-2, FGF-5, IGF-1, TGF- $\beta$ , BMP-2, BMP-7, PDGF, VEGF.]

**[24.** A sterile cartilage defect repair material as claimed in claim 21 wherein said bioabsorbable carrier consists of sodium hyaluronate, hyaluronic acid and its derivatives.]

**[25.** A sterile cartilage defect material as claimed in claim 21 wherein said lyophilized cartilage pieces have a water content ranging from about 0.1% to 8.0%.]

**[26.** A sterile cartilage defect implant material as claimed in claim 21 wherein said allograft articular cartilage is hyaline cartilage.]

**[27.** A sterile allograft cartilage defect implant material as claimed in claim 21 wherein said milled cartilage is fibrous cartilage.]

**[28.** A sterile allograft cartilage defect implant material as claimed in claim 21 wherein said milled cartilage is hyaline and fibrous cartilage.]

**[29.** A sterile cartilage defect implant material as claimed in claim 21 wherein said milled cartilage ranges from about 25% to about 50% by weight and said carrier ranges from about 75% to about 50% by weight.]

**[30.** A sterile cartilage defect implant material as claimed in claim 21 wherein said milled cartilage ranges from about 15% to about 30% by weight with the carrier ranging from about 85% to about 70% by weight.]

**[31.** A sterile cartilage defect implant material comprising lyophilized milled allograft articular cartilage pieces ranging

from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers and autologous stem cells in an amount exceeding the natural occurrence of same in a patient being treated.]

**[32.** A method of placing a cartilage defect material in a cartilage defect, said cartilage defect material comprising milled allograft articular cartilage which has been lyophilized and mixed in a bioabsorbable carrier comprising the steps of:

(a) cutting a patient's tissue at a site of a cartilage defect to remove a diseased area of cartilage;

(b) adding autologous cells to said mixture of milled allograft cartilage in a bioabsorbable carrier;

(c) placing a mixture of milled allograft cartilage with added autologous cells in a bioabsorbable carrier in the cartilage defect area where cartilage has been removed; and

(d) placing a cover over the mixture of milled allograft cartilage in a bioabsorbable carrier to contain the mixture in cartilage defect site for a predetermined period of time.]

**[33.** The method of claim 32 wherein growth factors are added to said mixture.]

**[34.** The method of claim 32 wherein said autologous cells are chondrocytes.]

**[35.** The method of claim 32 wherein said autologous cells are bone marrow cells.]

**[36.** The method of claim 32 wherein said autologous cells are stem cells.]

**[37.** A sterile cartilage defect implant material comprising lyophilized milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives and chitosan and autologous chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage, wherein said milled cartilage ranges from about 25% to about 50% by weight and said bioabsorbable carrier ranges from about 75% to about 50% by weight.]

**[38.** A sterile cartilage defect implant material comprising lyophilized milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of gelatin, collagen and alginate and autologous chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage, wherein said milled cartilage ranges from about 25% to about 50% by weight and said bioabsorbable carrier ranges from about 75% to about 50% by weight.]

**[39.** A sterile cartilage defect implant material comprising lyophilized milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of buffered PBS, Dextran or polymers and autologous chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage, wherein said milled cartilage ranges from about 25% to about 50% by weight and said bioabsorbable carrier ranges from about 75% to about 50% by weight.]

*40. A cartilage defect repair material for use in human beings, comprising a mixture having a bioabsorbable carrier and freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said mixture being in the form of a gel.*

*41. A cartilage defect repair material for use in human beings, comprising a mixture having a bioabsorbable carrier and freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said mixture being in the form of a paste,*



and said cartilage pieces being present in said mixture in an amount within the range of from about 25% to about 50% by weight.

42. A cartilage defect repair material for use in human beings, comprising a mixture having a bioabsorbable carrier and freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said mixture being in the form of one of a paste and a gel, and said cartilage pieces being present in said mixture in an amount within the range of from about 15% to about 50% by weight.

43. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage pieces are formed from allograft cartilage having a reduced water content.

44. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage pieces are formed from allograft cartilage having a reduced water content within the range of about 0.1% to about 8.0% by weight.

45. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage pieces are formed from allograft cartilage that has been lyophilized so as to reduce its water content to an amount within the range of about 0.1% to about 8.0% by weight.

46. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said size is in the range of 0.01 mm to 1.0 mm.

47. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said allograft cartilage pieces are allograft articular cartilage pieces.

48. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said allograft cartilage pieces include hyaline cartilage.

49. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said allograft cartilage pieces lack cell viability.

50. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage defect repair material is free of added chondrocytes.

51. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage defect repair material is free of bone pieces.

52. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said mixture is formed for implantation directly in a defect site.

53. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said allograft cartilage pieces have an ability to promote the growth of new articular cartilage in a cartilage defect.

54. A cartilage defect repair material as claimed in claim 40, wherein said allograft cartilage pieces are present in said mixture in an amount in the range of from about 15% to about 30% by weight and said bioabsorbable carrier is present in said mixture in an amount in the range of from about 70% to about 85% by weight.

55. A cartilage defect repair material as claimed in claim 41, wherein said bioabsorbable carrier is present in said mixture at an amount in the range of from about 50% to about 75% by weight.

56. A cartilage defect repair material as claimed in claim 42, wherein said bioabsorbable carrier is present in said mixture in an amount within the range of from about 50% to about 85% by weight.

57. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage pieces are formed by freezing allograft cartilage with liquid nitrogen and milling the frozen cartilage.

58. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said allograft cartilage pieces are formed by milling frozen allograft articular cartilage.

59. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage pieces are formed by freeze-milling allograft cartilage subsequent to reducing the water content of the allograft cartilage.

60. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said allograft cartilage pieces are formed by a process including the steps of harvesting a donor tissue consisting essentially of articular cartilage, reducing the water content of said donor tissue, and freeze-milling said donor tissue.

61. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, said mixture including a bioabsorbable carrier, and said allograft cartilage pieces including fibrocartilage.

62. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, said mixture including a bioabsorbable carrier, and said allograft cartilage pieces including hyaline cartilage and fibrocartilage.

63. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier and a protein glue.

64. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier selected from the group consisting of sodium hyaluronate, hyaluronic acid, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, and polymers.

65. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier selected from the group consisting of sodium hyaluronate and hyaluronic acid.

66. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier and an additive selected from the group consisting of a growth factor, human allogenic cells, human allogenic bone marrow cells, human autologous bone marrow cells, human allogenic stem cells, human autologous stem cells, human demineralized bone matrix, insulin, insulin-like growth factor-1, interleukin-1 receptor agonist, hepatocyte growth factor, platelet-derived growth factor, Indian hedgehog, and parathyroid hormone-related peptide.

67. A cartilage defect repair material as claimed in claim 66, wherein said growth factor is selected from the group consisting of FGF-2, FGF-5, IGF-1, TGF- $\beta$ , BMP-2, BMP-7, PDGF, and VEGF.

68. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier and autologous chondrocytes at a concentration greater than the concentration of chondrocytes

that are naturally present in hyaline cartilage of a human being having an age in the range of 20 years to 55 years.

69. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier and allogenic chondrocytes at a concentration greater than the concentration of chondrocytes that are naturally present in hyaline cartilage of a human being having an age in the range of 20 years to 55 years.

70. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier and autologous bone marrow cells at a concentration greater than the concentration of bone marrow cells that are naturally present in hyaline cartilage of a human being having an age in the range of 20 years to 55 years.

71. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier and autologous stem cells at a concentration greater than the concentration of stem cells that are naturally present in hyaline cartilage of a human being having an age in the range of 20 years to 55 years.

72. A method of repairing a cartilage defect in a human being, comprising the step of placing in a defect site freeze-milled allograft cartilage pieces having a size not greater than 1 mm.

73. A method as claimed in claim 72, wherein the cartilage pieces have a water content within the range of about 0.1% to about 8.0% by weight prior to their placement in the defect site.

74. A method as claimed in claim 72, wherein the cartilage pieces are formed from allograft cartilage having a reduced water content.

75. A method as claimed in claim 72, wherein the cartilage pieces are formed from allograft cartilage which has been dried so as to reduce its water content to an amount within the range of about 0.1% to about 8.0% by weight.

76. A method as claimed in claim 72, wherein the size of the cartilage pieces ranges from 0.01 mm to 1.0 mm.

77. A method as claimed in claim 72, wherein the cartilage pieces are formed by freezing allograft cartilage with liquid nitrogen and milling the frozen cartilage.

78. A method as claimed in claim 72, wherein the cartilage pieces are formed by freeze-milling allograft cartilage subsequent to reducing the water content of the allograft cartilage.

79. A method as claimed in claim 72, wherein the defect site includes a defect in articular cartilage.

80. A method as claimed in claim 72, wherein the freeze-milled allograft cartilage pieces consist essentially of articular cartilage.

81. A method as claimed in claim 72, wherein the freeze-milled allograft cartilage pieces lack cell viability.

82. A method as claimed in claim 72, comprising the further steps of harvesting a donor tissue consisting essentially of articular cartilage, reducing the water content of said donor tissue, and freeze-milling said donor tissue.

83. A method as claimed in claim 72, comprising the further step of forming the freeze-milled allograft cartilage pieces by a process including the step of milling frozen allograft articular cartilage.

84. A method as claimed in claim 72, wherein the allograft cartilage pieces are free of added chondrocytes.

85. A method as claimed in claim 79, wherein the cartilage pieces have an ability to promote the growth of new articular cartilage in the articular cartilage defect.

86. A method as claimed in claim 72, comprising the further steps of cutting a patient's tissue to remove a diseased area of cartilage from the defect site; and placing a cover over the allograft cartilage pieces so as to contain the allograft cartilage pieces in the defect site.

87. A method as claimed in claim 86, further comprising the step of adding cells to the defect site.

88. A method as claimed in claim 87, wherein the cells are selected from the group consisting of chondrocytes, bone marrow cells and stem cells.

89. A method as claimed in claim 72, wherein the cartilage pieces are included in a mixture, the mixture including a bioabsorbable carrier.

90. A method as claimed in claim 89, wherein said placing step includes the step of placing the mixture in the defect site, said method comprising the further steps of cutting a patient's tissue to remove a diseased area of cartilage from the defect site; and placing a cover over the mixture so as to contain the mixture in the defect site.

91. A method as claimed in claim 90, further comprising the step of adding cells to the defect site.

92. A method as claimed in claim 91, wherein the cells are selected from the group consisting of chondrocytes, bone marrow cells and stem cells.

93. A method as claimed in claim 90, comprising the further step of adding a growth factor to the mixture.

94. A method as claimed in claim 90, further comprising the step of fixing the mixture in the cartilage defect site with an organic glue.

95. A method as claimed in claim 90, further comprising the step of keeping the cover over the mixture for a predetermined period of time that is sufficient to promote cartilage growth at the defect site.

96. A method as claimed in claim 90, wherein the cover is selected from the group consisting of a periosteal flap and a perichondrial flap.

97. A method for making a cartilage defect repair material for use in human beings from allograft cartilage, said method comprising the steps of freeze-milling the allograft cartilage so as to form freeze-milled allograft cartilage pieces having a size not greater than 1 mm; and mixing the freeze-mill cartilage pieces with a bioabsorbable carrier to form a mixture in the form of a gel.

98. A method for making a cartilage defect repair material for use in human beings from allograft cartilage, said method comprising the steps of freeze-milling the allograft cartilage so as to form freeze-milled allograft cartilage pieces having a size not greater than 1 mm; and mixing the freeze-mill cartilage pieces with a bioabsorbable carrier to form a mixture in the form of a paste, the freeze-milled cartilage pieces being present in the mixture in an amount within the range of from about 25% to about 50% by weight.

99. A method for making a cartilage defect repair material for use in human beings from allograft cartilage, said method comprising the steps of freeze-milling the allograft cartilage so as to form freeze-milled allograft cartilage pieces having a size not greater than 1 mm; and mixing the freeze-mill cartilage pieces with a bioabsorbable carrier to form a mixture in the form of one of a paste and a gel, the freeze-milled cartilage pieces being present in the mixture in an amount within the range of from about 15% to about 50% by weight.

## 15

100. A method as claimed in any one of claims 97, 98 and 99, comprising the further step of reducing the water content of the allograft cartilage.

101. A method as claimed in claim 100, wherein said reducing step is performed so as to reduce the water content of the allograft cartilage to an amount within the range of about 0.1% to about 8.0% by weight.

102. A method as claimed in claim 100, wherein said reducing step is performed prior to said freeze-milling step.

103. A method as claimed in claim 100, wherein said reducing step includes the step of lyophilizing the allograft cartilage.

104. A method as claimed in any one of claims 97, 98 and 99, wherein said freeze-milling step includes the step of freezing the cartilage and the step of milling the frozen cartilage.

105. A method as claimed in any one of claims 97, 98 and 99, wherein said freeze-milling step is performed by milling the cartilage in a frozen state.

## 16

106. A method as claimed in any one of claims 97, 98 and 99, wherein the freeze-milled cartilage pieces have a water content within the range of about 0.1% to about 8.0% by weight.

107. A method as claimed in any one of claims 97, 98 and 99, wherein the size of the freeze-milled cartilage pieces ranges from 0.01 mm to 1.0 mm.

108. A method as claimed in any one of claims 97, 98 and 99, wherein the allograft cartilage includes allograft articular cartilage.

109. A method as claimed in any one of claims 97, 98 and 99, comprising the further step of harvesting the allograft cartilage from a donor tissue consisting essentially of articular cartilage.

110. A method as claimed in any one of claims 97, 41 and 42, wherein the mixture is formed for implantation directly in a defect site.

\* \* \* \* \*